Compositions and Methods Relating to Ionic Salts of Peptides

Abstract

The present invention relates to compounds of Formula I, compositions containing same, and methods of use.

1 .- 32 . (canceled) 
     
     
         33 . A compound of Formula I, or an enantiomer, polymorph, solvate, or hydrate thereof, which is a salt of an amino acid moiety and one or two fatty acids, A and B: 
       
         
           
           
               
               
           
         
         wherein 
         A and B are the same or different, and each of A and B is independently selected from the group consisting of linoleic acid, gamma-linolenic acid (GLA), eicosadienoic acid, dihomo-gamma-linolenic acid (DGLA), arachidonic acid (AA), docosadienoic acid, adrenic acid, docosapentaenoic acid (Osbond acid), tetracosatetraenoic acid, and tetracosapentaenoic acid, 24:5 (n-6). 
         either A or B, but not both, may be absent, 
         X 1  and X 2  are each independently selected from (CH 2 ) 3 —R 1 , and (CH 2 ) 4 —R 2 , where R 1  and R 2  are each a basic function which may be the same or different, the basic function being selected from the group consisting of a primary amine, a secondary amine, a tertiary amine, and a guanidine, and 
         X 3  is H. 
       
     
     
         34 . The compound of  claim 33 , wherein X 1  and X 2  are both (CH 2 ) 4 —R 2  and R 2  is NH 3 +. 
     
     
         35 . The compound of  claim 33 , wherein X 1  and X 2  are both (CH 2 ) 3 —R 1  and R 1  is NHC(NH 2 +)NH 2 . 
     
     
         36 . The compound of  claim 33 , wherein X 1  is (CH 2 ) 3 —R 1 , R 1  is NHC(NH 2 +)NH 2 , X 2  is (CH 2 ) 4 —R 2  and R 2  is NH 3 +. 
     
     
         37 . The compound of  claim 33 , wherein X 1  is (CH 2 ) 4 —R 2 , R 2  is NH 3 +, X 2  is (CH 2 ) 3 —R 1 , and R 1  is NHC(NH 2 +)NH 2 . 
     
     
         38 . A pharmaceutical composition comprising the compound of  claim 33 , and a carrier. 
     
     
         39 . The pharmaceutical composition of  claim 38 , wherein the composition is a solid oral dosage form. 
     
     
         40 . The pharmaceutical composition of  claim 38 , wherein the composition is an intravenous dosage form. 
     
     
         41 . The pharmaceutical composition of  claim 38 , wherein the composition is an ophthalmic formulation. 
     
     
         42 . The pharmaceutical composition of  claim 38 , wherein the composition is a parenteral dosage form. 
     
     
         43 . A package or kit comprising a unit dosage form of the pharmaceutical composition of  claim 38 , at least one container for holding the unit dosage forms, and instructions for use. 
     
     
         44 . The compound of  claim 34 , wherein A or B is absent and the remainder is arachidonic acid (AA). 
     
     
         45 . The compound of  claim 34 , wherein A and B are both present and are each is arachidonic acid (AA). 
     
     
         46 . The compound of  claim 35 , wherein A or B is absent and the remainder is arachidonic acid (AA). 
     
     
         47 . The compound of  claim 35 , wherein A and B are both present and are each is arachidonic acid (AA). 
     
     
         48 . The compound of  claim 36 , wherein A or B is absent and the remainder is arachidonic acid (AA). 
     
     
         49 . The compound of  claim 36 , wherein A and B are both present and are each is arachidonic acid (AA). 
     
     
         50 . The compound of  claim 37 , wherein A or B is absent and the remainder is arachidonic acid (AA). 
     
     
         51 . The compound of  claim 37 , wherein A and B are both present and are each is arachidonic acid (AA). 
     
     
         52 . A composition comprising a compound of  claim 33 . 
     
     
         53 . The composition of  claim 52 , wherein the composition is a dietary supplement or nutraceutical additive. 
     
     
         54 . A method for treating a metabolic disease or disorder in a human subject, the method comprising administering to the subject a pharmaceutical composition comprising the compound of  claim 33 , wherein the metabolic disease or disorder is selected from the group consisting of hypertriglyceridemia, severe hypertriglyceridemia, hypercholesterolemia, pre-diabetes, fatty liver disease, and obesity. 
     
     
         55 . A method for treating a cardiovascular disease or disorder in a subject, the method comprising administering to the subject a pharmaceutical composition comprising the compound of  claim 33 , wherein the cardiovascular disease or disorder is selected from the group consisting of atrial fibrillation, myocardial infarction, and congestive heart failure. 
     
     
         56 . A method for treating an inflammatory disease or disorder in a subject, the method comprising administering to the subject a pharmaceutical composition comprising the compound of  claim 33 , wherein the inflammatory disease or disorder is selected from the group consisting of arthritis, irritable bowel syndrome, ophthalmic inflammation disorders, and dry eye syndrome. 
     
     
         57 . A method for treating a gastrointestinal disorder or complication thereof in a subject, the method comprising administering to the subject a pharmaceutical composition comprising the compound of  claim 33 , wherein the gastrointestinal disorder or complication thereof is selected from the group consisting of bowel obstruction, short bowel syndrome, Gastroschisis, prolonged diarrhea, high-output fistula, Crohn's disease, ulcerative colitis, colon cancer, familial adenomatous polyposis, parenteral nutrition-associated liver disease, essential fatty acid deficiency, a congenital gastrointestinal anomaly, and necrotizing enterocolitis. 
     
     
         58 . A method for treating a neurological disorder in a subject, the method comprising administering to the subject a pharmaceutical composition comprising the compound of  claim 33 , wherein the neurological disorder is selected from the group consisting of Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), depression, traumatic brain injury, spinal cord injury, ischemic stroke, and concussion.